Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Decipher Labs Ltd
Your Vote -
Buy
83.33%
Hold
0.00%
Sell
16.67%
83.33%
6 users have voted
Option Chain
Analyzes market sentiment, predicts Decipher Labs Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Decipher Labs - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
-
Decipher Labs - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Decipher Labs has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Decipher Labs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Key fundamentals
Evaluate the intrinsic value of Decipher Labs Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 8.9276 | 8.9043 | 11.5217 | 11.2976 | 11.2955 |
| Liabilities | 8.9276 | 8.9043 | 11.5217 | 11.2976 | 11.2955 |
| Equity | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 |
| Gross Profit | 0.0197 | -0.3682 | 0.3621 | 0.0155 | 0.1578 |
| Net Profit | 0.0233 | -2.6175 | 0.3604 | 0.0962 | 0.168 |
| Cash From Operating Activities | -0.0297 | -0.0765 | 0.5478 | 0.2725 | -0.0103 |
| NPM(%) | 0.65 | -323.14 | 36.46 | 9.85 | 11.8 |
| Revenue | 3.5316 | 0.81 | 0.9884 | 0.976 | 1.4235 |
| Expenses | 3.5119 | 1.1782 | 0.6263 | 0.9605 | 1.2657 |
| ROE(%) | 0.1 | -12.15 | 1.67 | 0.44 | 0.78 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Decipher Labs Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 810.05 | -1.12 | 26.88 | 7.05 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 74.39 | 0.39 | 308.58 | 25.70 | 14.01 | 0.68 |
| Bharat Immunological and Biologicals Corporation Ltd | 25.66 | -5.45 | 0.00 | 53.37 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 698.00 | -1.87 | 0.00 | 24.24 | -687.11 | 0.00 |
Company Info
M/s. Combat Drugs Limited was incorporated as a Private Limited Company on 18th September, 1986. The Company was converted into a Public Limited Company on llth June, 1992. The Company was promoted by Mr. Suchit Mohan Lal who has vast experience in Marketing of Pharmaceutical Formulations and Mr. Ajay Karan who has experience in the Production as well as Marketing of pharmaceutical formulations. The Commercial Production of the company started in July, 1987 on Loan Licence basis. The company acquired a full fledged manufacturing unit located at Balanagar, Hyderabad on lease from M/s. Fairchild Laboratories Pvt. Ltd. and commenced Production from the said unit in August, 1988. In July, 1992 the Manufacturing activities of the Company were shifted to the present leased premises at 18A, Kushaiguda, Hyderabad. The Lease for the present premises is initially for a period of 3 years w.e.f June, 1992 which can be extended for a further period of 2 years with mutual consent. The total constructed area of 7200 Sft. is conforming to the requirements of a Pharmaceutical Unit and can accomodate Tablet, Capsule and Liquid Sections along with Laboratory, including facilities to manufacture Hi-tec Formulations with little modifications. Utilities like Power, water etc are already available on the Unit. 2011 - the Company have approved the scheme of arrangement between the company and its members and unsecured creditors. 2020 -Company name has changed to Decipher Labs Ltd. from Combat Drugs Ltd.
M/s. Combat Drugs Limited was incorporated as a Private Limited Company on 18th September, 1986. The Company was converted into a Public Limited Company on llth June, 1992. The Company was promoted by Mr. Suchit Mohan Lal who has vast experience in Marketing of Pharmaceutical Formulations and Mr. Ajay Karan who has experience in the Production as well as Marketing of pharmaceutical formulations. The Commercial Production of the company started in July, 1987 on Loan Licence basis. The company acquired a full fledged manufacturing unit located at Balanagar, Hyderabad on lease from M/s. Fairchild Laboratories Pvt. Ltd. and commenced Production from the said unit in August, 1988. In July, 1992 the Manufacturing activities of the Company were shifted to the present leased premises at 18A, Kushaiguda, Hyderabad. The Lease for the present premises is initially for a period of 3 years w.e.f June, 1992 which can be extended for a further period of 2 years with mutual consent. The total constructed area of 7200 Sft. is conforming to the requirements of a Pharmaceutical Unit and can accomodate Tablet, Capsule and Liquid Sections along with Laboratory, including facilities to manufacture Hi-tec Formulations with little modifications. Utilities like Power, water etc are already available on the Unit. 2011 - the Company have approved the scheme of arrangement between the company and its members and unsecured creditors. 2020 -Company name has changed to Decipher Labs Ltd. from Combat Drugs Ltd.
Read More
Parent Organisation
Decipher Labs Ltd.
Founded
17/09/1986
Managing Director
NSE Symbol
FAQ
The current price of Decipher Labs Ltd is
The 52-week high for Decipher Labs Ltd is
The market capitalization of Decipher Labs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Decipher Labs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Decipher Labs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Decipher Labs Ltd shares.
The CEO of Decipher Labs Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
